AVRO Avrobio Inc.

Avrobio Inc is a clinical stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose.

$0.87
As of 12/02/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/21/2018
Outstanding shares:  43,774,088
Average volume:  337,970
Market cap:   $39,173,431
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BF2G3Y5
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.27
PS ratio:   0.00
Return on equity:   -85.26%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy